- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 230 Pages
Global
From €2177EUR$2,290USD£1,829GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- December 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- August 2024
- 114 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Drug Pipelines
- March 2025
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- June 2024
- 105 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- March 2025
Global
From €300EUR$338USD£261GBP
- Report
- February 2024
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- June 2023
- 116 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2022
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2018
- 195 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- December 2023
- 157 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- March 2021
- 48 Pages
Global
€20914EUR$22,000USD£17,570GBP

Denosumab is a monoclonal antibody used to treat endocrine and metabolic disorders. It is used to treat osteoporosis, Paget's disease of bone, and bone metastases from solid tumors. It works by inhibiting the activity of osteoclasts, which are cells that break down bone. This helps to reduce bone loss and increase bone density. Denosumab is administered as an injection under the skin or into a vein.
Denosumab is a relatively new drug, and is still in the process of being approved for use in various countries. It is currently approved in the United States, Canada, Europe, and other countries. It is also being studied for use in other endocrine and metabolic disorders.
Some companies in the Denosumab market include Amgen, Novartis, and Merck. Show Less Read more